CYLD
Ubiquitin carboxyl-terminal hydrolase CYLD
Also known as: CYLD_HUMAN, CYLD1, KIAA0849, USPL2
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9NQC7
- Gene
- CYLD
- Ensembl
- ENSG00000083799
- Chromosome
- 16
- Canonical length
- 956 aa
- Protein class
- Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Primary cilium transition zone,Centriolar satellite,Basal body,Principal piece
OverviewNCBI Gene
This gene is encodes a cytoplasmic protein with three cytoskeletal-associated protein-glycine-conserved (CAP-GLY) domains that functions as a deubiquitinating enzyme. Mutations in this gene have been associated with cylindromatosis, multiple familial trichoepithelioma, and Brooke-Spiegler syndrome. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
956 residues, UniProt reviewed canonical sequence.
>Q9NQC7|CYLD
1 MSSGLWSQEK VTSPYWEERI FYLLLQECSV TDKQTQKLLK VPKGSIGQYI QDRSVGHSRI
61 PSAKGKKNQI GLKILEQPHA VLFVDEKDVV EINEKFTELL LAITNCEERF SLFKNRNRLS
121 KGLQIDVGCP VKVQLRSGEE KFPGVVRFRG PLLAERTVSG IFFGVELLEE GRGQGFTDGV
181 YQGKQLFQCD EDCGVFVALD KLELIEDDDT ALESDYAGPG DTMQVELPPL EINSRVSLKV
241 GETIESGTVI FCDVLPGKES LGYFVGVDMD NPIGNWDGRF DGVQLCSFAC VESTILLHIN
301 DIIPALSESV TQERRPPKLA FMSRGVGDKG SSSHNKPKAT GSTSDPGNRN RSELFYTLNG
361 SSVDSQPQSK SKNTWYIDEV AEDPAKSLTE ISTDFDRSSP PLQPPPVNSL TTENRFHSLP
421 FSLTKMPNTN GSIGHSPLSL SAQSVMEELN TAPVQESPPL AMPPGNSHGL EVGSLAEVKE
481 NPPFYGVIRW IGQPPGLNEV LAGLELEDEC AGCTDGTFRG TRYFTCALKK ALFVKLKSCR
541 PDSRFASLQP VSNQIERCNS LAFGGYLSEV VEENTPPKME KEGLEIMIGK KKGIQGHYNS
601 CYLDSTLFCL FAFSSVLDTV LLRPKEKNDV EYYSETQELL RTEIVNPLRI YGYVCATKIM
661 KLRKILEKVE AASGFTSEEK DPEEFLNILF HHILRVEPLL KIRSAGQKVQ DCYFYQIFME
721 KNEKVGVPTI QQLLEWSFIN SNLKFAEAPS CLIIQMPRFG KDFKLFKKIF PSLELNITDL
781 LEDTPRQCRI CGGLAMYECR ECYDDPDISA GKIKQFCKTC NTQVHLHPKR LNHKYNPVSL
841 PKDLPDWDWR HGCIPCQNME LFAVLCIETS HYVAFVKYGK DDSAWLFFDS MADRDGGQNG
901 FNIPQVTPCP EVGEYLKMSL EDLHSLDSRR IQGCARRLLC DAYMCMYQSP TMSLYKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against CYLD can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.37
- Highest tissue expression
- 89 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 89 nTPM
- lymph node: 50 nTPM
- tonsil: 45 nTPM
- spleen: 37 nTPM
- appendix: 37 nTPM
- testis: 36 nTPM
Single-cell type
- neutrophils: 362 nCPM
- t-cells: 171 nCPM
- neutrophil progenitors: 167 nCPM
- suprabasal keratinocytes: 165 nCPM
- ocular epithelial cells: 155 nCPM
- b-cells: 148 nCPM
Immune cell
- basophil: 65 nTPM
- eosinophil: 38 nTPM
- T-reg: 38 nTPM
- neutrophil: 32 nTPM
- memory CD4 T-cell: 27 nTPM
- NK-cell: 26 nTPM
Brain region
- thalamus: 79 nTPM
- midbrain: 69 nTPM
- pons: 60 nTPM
- amygdala: 60 nTPM
- hypothalamus: 59 nTPM
- basal ganglia: 58 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about CYLD.
Disease | AllUniProt
Conditions CYLD is implicated in, by any mechanism.
- Cylindromatosis, familial (FCYL) MIM:132700
- Trichoepithelioma, multiple familial, 1 (MFT1) MIM:601606
- Brooke-Spiegler syndrome (BRSS) MIM:605041
- Frontotemporal dementia and/or amyotrophic lateral sclerosis 8 (FTDALS8) MIM:619132
Disease | GeneticClinVar
74 pathogenic / likely-pathogenic of 444 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Familial cylindromatosis
- Brooke-Spiegler syndrome
- Frontotemporal dementia and/or amyotrophic lateral sclerosis 8
- Familial multiple trichoepitheliomata
- Trichoepithelioma, multiple familial, 1
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.2
- gnomAD pLI
- 1
- gnomAD missense Z
- 3.55
- DepMap mean gene effect
- -0.02
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- CD4-positive or CD8-positive, alpha-beta T cell lineage commitment
- homeostasis of number of cells
- innate immune response
- necroptotic process
- negative regulation of canonical NF-kappaB signal transduction
- negative regulation of canonical Wnt signaling pathway
- negative regulation of inflammatory response
- negative regulation of JNK cascade
- negative regulation of NF-kappaB transcription factor activity
- negative regulation of non-canonical NF-kappaB signal transduction
- negative regulation of p38MAPK cascade
- negative regulation of type I interferon production
- nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway
- positive regulation of extrinsic apoptotic signaling pathway
- positive regulation of protein localization
- positive regulation of T cell differentiation
- positive regulation of T cell receptor signaling pathway
- protein deubiquitination
- protein K63-linked deubiquitination
- protein linear deubiquitination
- proteolysis
- regulation of B cell differentiation
- regulation of cilium assembly
- regulation of inflammatory response
- regulation of intrinsic apoptotic signaling pathway
- regulation of microtubule cytoskeleton organization
- regulation of mitotic cell cycle
- regulation of necroptotic process
- regulation of tumor necrosis factor-mediated signaling pathway
- ripoptosome assembly involved in necroptotic process
- Wnt signaling pathway
- negative regulation of interleukin-18-mediated signaling pathway
Molecular functions
- cysteine-type deubiquitinase activity
- K48-linked deubiquitinase activity
- K63-linked deubiquitinase activity
- proline-rich region binding
- protein kinase binding
- zinc ion binding
- Met1-linked polyubiquitin deubiquitinase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- CAP Gly-rich domain
- Peptidase C19, ubiquitin carboxyl-terminal hydrolase
- Ubiquitin specific protease, conserved site
- Ubiquitin specific protease UPS, catalytic domain
- CAP Gly-rich domain superfamily
- Papain-like cysteine peptidase superfamily
- Ubiquitin carboxyl-terminal hydrolase
- CAP-Gly domain
- Phosphorylation region of CYLD, unstructured
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of CYLD in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CYLD as an antibody target. Whether an autoantibody or antibody against CYLD could matter depends on whether native CYLD is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CYLD is annotated at the cell surface, where native CYLD is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label CYLD as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...